SCHEMBL5477362

SCHEMBL5477362

CN1CCN(c2ccc(Nc3ncc(-c4cccc(OCc5ccccc5)c4)o3)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
USP2 O75604 1/20 0.55
MAPK1 P28482 1/20 0.55
KMT2A Q03164 1/20 0.55
ESR2 Q92731 1/20 0.55
TAAR1 Q96RJ0 1/20 0.55
VCP P55072 3/20 0.52
PRKDC P78527 1/20 0.48
ATM Q13315 1/20 0.48
MAP4K1 Q92918 2/20 0.47
KDR P35968 4/20 0.46
FYN P06241 1/20 0.46
FLT1 P17948 3/20 0.45
FLT4 P35916 3/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469448 0.89 BRD4 (0.55) MAPTKMT2AVCPMAP4K1KDR
SCHEMBL5184581 0.87 VCP (0.52) MAPTMAPK1TAAR1VCPMAP4K1
SCHEMBL5472158 0.87 VCP (0.67) VCPKDRFLT1FLT4KDM4E
SCHEMBL5464712 0.86 VCP (0.51) VCPMAP4K1KDRFLT1FLT4
SCHEMBL5465435 0.85 VCP (0.52) MAPTUSP2MAPK1KMT2AESR2
SCHEMBL23554186 0.84 KDR (0.62) VCPPRKDCATMKDRFLT1
SCHEMBL5475517 0.84 VCP (0.62) VCPMAP4K1KDRFLT1FLT4
SCHEMBL5472810 0.84 BRD4 (0.56) MAPTVCPMAP4K1KDRTDP1
SCHEMBL5186408 0.83 VCP (0.61) VCPMAP4K1KDRFYNFLT1
SCHEMBL5475253 0.82 VCP (0.50) VCPMAP4K1KDRFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US claimed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US claimed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142437-A1 CHEMICAL COMPOUNDS CDK4, CDK2, CDK3 MAPT 3337/4885USP2 2383/4885MAPK1 500/4885
US-20050288515-A1 Chemical compounds CDK4, CDK2, CDK3 MAPT 3337/4885USP2 2383/4885MAPK1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.